NCT06753331View on ClinicalTrials.gov

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2029

Conditions
Parkinson's Disease
Interventions
COMBINATION_PRODUCT

DSP-1083 implantation

DSP-1083 subjects will receive 2.7M viable cells per hemisphere; 5.4M total cell dose as implants.

PROCEDURE

Sham surgery treatment

Sham surgery subjects will undergo a partial thickness burr hole surgical procedure on each side of the skull with no DSP-1083 administration.

Trial Locations (2)

10032

RECRUITING

New York Presbyterian Hospital-Columbia University Medical Center, New York

40536

RECRUITING

University of Kentucky Medical Center, Lexington

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY